Korea adds Pergoveris pen to reimbursement rolls, vial already covered
This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
Pricing & Reimbursement
CDA-AMC reverses course, backs Leqembi’s first ruling content still undisclosed
Four words carry the news: follows a reconsideration. CDA-AMC reached a different conclusion first, and neither release says what it was.
Nine More Drugmakers Signed MFN Deals. The Coalition Formed to Fight Them Did Not.
The useful information is who is absent. The mid-sized biotech coalition formed to contest MFN has no member among the nine signatories.
Korea Runs Three Reimbursement Speeds. September Shows All Three at Once.
The lane determines the timeline, and it is set long before you file. Model the Korean queue, not the approval date.
The Number Everyone Will Quote About European Launches Rests on Eleven Products
The 22.9% figure driving coverage of European launch delays is 48 products falling to 37. The pricing finding underneath it is stronger and barely quoted.
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It
Health Canada cleared Vanrafia on a Week 36 proteinuria readout. Novartis will not take that same package into Canadian pricing review.
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route
QuickAccess read/Oncology/Antibody CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route Athithi Verma· 19 August 2026· 2 min read· Synopulse The 60-day comment period on CMS-4215-P closed at 5pm on 17 August 2026. The proposed rule, published in the Federal Register on 16 June 2026, would codify … Read more
Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision.
The sharpest advice in the roadmap is about vocabulary. Payers will not fund wellness, and in women’s health that classification is partly a choice.
The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.
The label credits outcomes trials run on statins and monoclonal antibody PCSK9 inhibitors. LEROCHOL is neither, and has no outcomes trial of its own.
Two Dominican High-Cost Lists Overlap by Only 44 Products. FOMAC Would Be a Third.
The country already covers this. Two schemes list 120 and 115 high-cost medicines, overlapping by 44. FOMAC would be a third list, starting at 13.